Mevastatin

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C23H34O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UQM1K0W9X, chemically known as 1,2,6,7,8,8a-hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone but generally known as mevastatin, which bears US NIH Compound Identifier 53232. European Medicines Agency schedules Mevastatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08927MIG. The term MEVASTATIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, No. 5 1981, List 21). MEVASTATIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, MEVASTATIN remains the US FDA Preferred Term for this commodity. Mevastatin bears US NLM identifiers UMLS ID C0056170 and NCI Concept Code C96285. SMILES: O(C1C2C(C(C=CC2=CC(C1)C)C)CCC1OC(=O)CC(O)C1)C(=O)C(CC)C.